268 related articles for article (PubMed ID: 32740973)
1. Ten-Eleven Translocation 1 Promotes Malignant Progression of Cholangiocarcinoma With Wild-Type Isocitrate Dehydrogenase 1.
Bai X; Zhang H; Zhou Y; Nagaoka K; Meng J; Ji C; Liu D; Dong X; Cao K; Mulla J; Cheng Z; Mueller W; Bay A; Hildebrand G; Lu S; Wallace J; Wands JR; Sun B; Huang CK
Hepatology; 2021 May; 73(5):1747-1763. PubMed ID: 32740973
[TBL] [Abstract][Full Text] [Related]
2. Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas.
Müller T; Gessi M; Waha A; Isselstein LJ; Luxen D; Freihoff D; Freihoff J; Becker A; Simon M; Hammes J; Denkhaus D; zur Mühlen A; Pietsch T; Waha A
Am J Pathol; 2012 Aug; 181(2):675-83. PubMed ID: 22688054
[TBL] [Abstract][Full Text] [Related]
3. Enhanced expression of ten-eleven translocation 1 reverses gemcitabine resistance in cholangiocarcinoma accompanied by a reduction in P-glycoprotein expression.
Wang C; Ye H; Zhang L; Cheng Y; Xu S; Zhang P; Zhang Z; Bai J; Meng F; Zhong L; Shi G; Li H
Cancer Med; 2019 Mar; 8(3):990-1003. PubMed ID: 30784212
[TBL] [Abstract][Full Text] [Related]
4. Aspartate beta-hydroxylase promotes cholangiocarcinoma progression by modulating RB1 phosphorylation.
Huang CK; Iwagami Y; Zou J; Casulli S; Lu S; Nagaoka K; Ji C; Ogawa K; Cao KY; Gao JS; Carlson RI; Wands JR
Cancer Lett; 2018 Aug; 429():1-10. PubMed ID: 29733964
[TBL] [Abstract][Full Text] [Related]
5. Mutation of
Su L; Zhang X; Zheng L; Wang M; Zhu Z; Li P
Front Endocrinol (Lausanne); 2020; 11():189. PubMed ID: 32373065
[No Abstract] [Full Text] [Related]
6. MicroRNA-191 acts as a tumor promoter by modulating the TET1-p53 pathway in intrahepatic cholangiocarcinoma.
Li H; Zhou ZQ; Yang ZR; Tong DN; Guan J; Shi BJ; Nie J; Ding XT; Li B; Zhou GW; Zhang ZY
Hepatology; 2017 Jul; 66(1):136-151. PubMed ID: 28194813
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of RSPO3 via targeted promoter DNA demethylation inhibits the progression of cholangiocarcinoma.
Wu G; Wang D; Xiong F; Liu W; Wang Q; Chen J; Wang B; Chen Y
Clin Epigenetics; 2023 Nov; 15(1):177. PubMed ID: 37932819
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
9. Circulating Oncometabolite 2-hydroxyglutarate as a Potential Biomarker for Isocitrate Dehydrogenase (IDH1/2) Mutant Cholangiocarcinoma.
Lee CL; O'Kane GM; Mason WP; Zhang WJ; Spiliopoulou P; Hansen AR; Grant RC; Knox JJ; Stockley TL; Zadeh G; Chen EX
Mol Cancer Ther; 2024 Mar; 23(3):394-399. PubMed ID: 38015561
[TBL] [Abstract][Full Text] [Related]
10. IDH1/2 Mutants Inhibit TET-Promoted Oxidation of RNA 5mC to 5hmC.
Xu Q; Wang K; Wang L; Zhu Y; Zhou G; Xie D; Yang Q
PLoS One; 2016; 11(8):e0161261. PubMed ID: 27548812
[TBL] [Abstract][Full Text] [Related]
11. GSG2 knockdown suppresses cholangiocarcinoma progression by regulating cell proliferation, apoptosis and migration.
Zhou J; Nie W; Yuan J; Zhang Z; Mi L; Wang C; Huang R
Oncol Rep; 2021 Jun; 45(6):. PubMed ID: 33846801
[TBL] [Abstract][Full Text] [Related]
12. Chronic ethanol-mediated hepatocyte apoptosis links to decreased TET1 and 5-hydroxymethylcytosine formation.
Ji C; Nagaoka K; Zou J; Casulli S; Lu S; Cao KY; Zhang H; Iwagami Y; Carlson RI; Brooks K; Lawrence J; Mueller W; Wands JR; Huang CK
FASEB J; 2019 Feb; 33(2):1824-1835. PubMed ID: 30188753
[TBL] [Abstract][Full Text] [Related]
13. Altered Expression of Oxidative Metabolism Related Genes in Cholangiocarcinomas.
Aukkanimart R; Boonmars T; Juasook A; Sriraj P; Boonjaraspinyo S; Wu Z; Laummuanwai P; Pairojkul C; Khuntikeo N; Rattanasuwan P
Asian Pac J Cancer Prev; 2015; 16(14):5875-81. PubMed ID: 26320466
[TBL] [Abstract][Full Text] [Related]
14. Characterization of TET and IDH gene expression in chronic lymphocytic leukemia: comparison with normal B cells and prognostic significance.
Van Damme M; Crompot E; Meuleman N; Maerevoet M; Mineur P; Bron D; Lagneaux L; Stamatopoulos B
Clin Epigenetics; 2016; 8():132. PubMed ID: 27980696
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of TET dioxygenases in seminomas associates with low levels of DNA methylation and hydroxymethylation.
Benešová M; Trejbalová K; Kučerová D; Vernerová Z; Hron T; Szabó A; Amouroux R; Klézl P; Hajkova P; Hejnar J
Mol Carcinog; 2017 Aug; 56(8):1837-1850. PubMed ID: 28218476
[TBL] [Abstract][Full Text] [Related]
16. Vitamin C in combination with inhibition of mutant IDH1 synergistically activates TET enzymes and epigenetically modulates gene silencing in colon cancer cells.
Gerecke C; Schumacher F; Berndzen A; Homann T; Kleuser B
Epigenetics; 2020 Mar; 15(3):307-322. PubMed ID: 31505989
[TBL] [Abstract][Full Text] [Related]
17. Upregulated LASP-1 correlates with a malignant phenotype and its potential therapeutic role in human cholangiocarcinoma.
Zhang H; Li Z; Chu B; Zhang F; Zhang Y; Ke F; Chen Y; Xu Y; Liu S; Zhao S; Liang H; Weng M; Wu X; Li M; Wu W; Quan Z; Liu Y; Zhang Y; Gong W
Tumour Biol; 2016 Jun; 37(6):8305-15. PubMed ID: 26729195
[TBL] [Abstract][Full Text] [Related]
18. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.
Borger DR; Goyal L; Yau T; Poon RT; Ancukiewicz M; Deshpande V; Christiani DC; Liebman HM; Yang H; Kim H; Yen K; Faris JE; Iafrate AJ; Kwak EL; Clark JW; Allen JN; Blaszkowsky LS; Murphy JE; Saha SK; Hong TS; Wo JY; Ferrone CR; Tanabe KK; Bardeesy N; Straley KS; Agresta S; Schenkein DP; Ellisen LW; Ryan DP; Zhu AX
Clin Cancer Res; 2014 Apr; 20(7):1884-90. PubMed ID: 24478380
[TBL] [Abstract][Full Text] [Related]
19. Elevated 2-oxoglutarate antagonizes DNA damage responses in cholangiocarcinoma chemotherapy through regulating aspartate beta-hydroxylase.
Nagaoka K; Bai X; Liu D; Cao K; Mulla J; Ji C; Chen H; Nisar MA; Bay A; Mueller W; Hildebrand G; Gao JS; Lu S; Setoyama H; Tanaka Y; Wands JR; Huang CK
Cancer Lett; 2024 Jan; 580():216493. PubMed ID: 37977350
[TBL] [Abstract][Full Text] [Related]
20. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer.
Saha SK; Parachoniak CA; Ghanta KS; Fitamant J; Ross KN; Najem MS; Gurumurthy S; Akbay EA; Sia D; Cornella H; Miltiadous O; Walesky C; Deshpande V; Zhu AX; Hezel AF; Yen KE; Straley KS; Travins J; Popovici-Muller J; Gliser C; Ferrone CR; Apte U; Llovet JM; Wong KK; Ramaswamy S; Bardeesy N
Nature; 2014 Sep; 513(7516):110-4. PubMed ID: 25043045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
